The effect of Niaspan (slow release nicotinic acid) on plasma phosphate, and renal phosphate handling in patents with severe chronic kidney disease - Niaspan in CKD

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-002982-35-GB

Enrollment

Registered

2005-08-09

Start date

2005-11-21

Completion date

Unknown

Last updated

2020-07-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic renal failure (CKD stages 4 &%)

Interventions

Trade Name: Niaspan Product Name: Niaspan Product Code: Niaspan Pharmaceutical Form: Trade Name: Phosex Product Name: Phosex Product Code: PL 14994/0001 Pharmaceutical Form: Tablet

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with CKD stages 4-5 Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Patients unable to give informed consent. Patients under the age of 18 years

Design outcomes

Primary

Measure	Time frame
Main Objective: To compare Niaspan with Phosex at normalising renal tubular handling of phosphate.;Secondary Objective: To compare Niaspan with Phosex at reducing serum phosphorus and PTH concentrations. To compare Niaspan with Phosex at increasing HDL:LDL ratio;Primary end point(s): Evaluation of TmPO4/GFR	—

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026